All news

Grail hits 12-month high on FDA panel win

Alpha Vantage · Yahoo Finance · · AI-summarised by FinFlash

Grail shares reached a 12-month high after an FDA advisory committee voted positively on its Galleri multi-cancer early detection test, moving it closer to marketing approval. Analysts see upside, with a $328.72 target versus a $229.28 price and 59 buy ratings. Pricing remains the key risk: the $949 list price will face insurer cost-benefit scrutiny, shaping adoption and profitability.

Read original source

NVDA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.